New Acute Myeloid Leukemia Treatments 2022

What is Acute Myeloid Leukemia (AML)?

Acute myeloid leukemia (AML) also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia is a cancer that starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), moving often into the blood, as well. It can sometimes spread to other parts of the body such as the liver, spleen, central nervous system (brain and spinal cord), and testicles. ¹

For the different types of AML, please visit the www.cancer.org website here.

Can Acute Myeloid Leukemia (AML) be cured?

Acute myeloid leukemia (AML) is mainly treated with Chemotherapy and begins as soon as possible. In some cases a combination of chemotherapy, radiotherapy and bone marrow or stem cell transplant might be needed. Thanks to recent advances in Acute Myeloid Leukemia (AML), treatments have shown to improve remission and cure rates.^2,3

What are the available Acute Myeloid Leukemia (AML) treatments?

There are several approved treatments for Acute Myeloid Leukemia (AML). Here are some of them:

Onureg (azacitidine)⁴

Onureg (azacitidine) is a nucleoside metabolic inhibitor (chemotherapy) indicated for the continued treatment of adult patients with Acute Myeloid Leukemia (AML) who had a first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy, and who are not able to complete intensive curative therapy.

Onureg (azacitidine) was approved by:

• The Food and Drug Administration (FDA), USA, on September 1, 2020, for the continued treatment of AML in patients in remission.
• The European Medicines Agency (EMA), in May 2020 as an injectable medicine under the name Vidaza for:

  - Myelodysplastic syndromes.

  - Chronic myelomonocytic leukaemia.

  - AML that has developed from a myelodysplastic syndrome.

  - AML when the bone marrow has more than 30% abnormal cells.

The FDA granted Priority Review and Orphan Drug designation to Onureg (azacitidine) for the treatment of advanced AML.

Venclyxto/Venclexta (venetoclax)^5,6

Venclyxto/Venclexta (venetoclax) is a B-Cell lymphoma-2 (BCL-2) inhibitor (chemotherapy) indicated as a combination treatment for newly diagnosed patients with Acute Myeloid Leukemia (AML).

On October 16, 2020 the Food and Drug Administration (FDA), USA approved Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Tibsovo (ivosidenib)⁷

Tibsovo (ivosidenib) is indicated for the treatment of newly-diagnosed Acute Myeloid Leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test, in adult patients who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Tibsovo (ivosidenib) was approved based on the results of study AG-120-C-001 (see 'Clinical Trials') by the Food and Drug Administration (FDA), USA on:

• July 20, 2018, for relapsed and refractory Acute Myeloid Leukemia (AML) with IDH1 mutation.
• May 02, 2019, for newly-diagnosed adult patients with IDH1 mutant Acute Myeloid Leukemia (AML) not eligible for intensive chemotherapy.
• The FDA previously granted Priority Review and Orphan Drug Designation to Tibsovo (ivosidenib).

If you are trying to access Acute Myeloid Leukemia (AML) treatments that are approved outside of your country of residence, we might be able to help you access it with the help of your treating doctor. You can read more about the medicines we can help you access and their price below:

Onureg (azacitidine)

Venclyxto/Venclexta (venetoclax)

Tibsovo (ivosidenib)

View all

Why access a new treatment for Acute Myeloid Leukemia (AML) with everyone.org?

everyone.org is registered in The Hague with the Dutch Ministry of Health (registration number 16258 G) as a pharmaceutical wholesale distributor. We have helped patients from over 85 countries to access thousands of medicines including. With a prescription from your treating doctor, you can count on our expert team to safely and legally guide you to access a treatment for AML. If you or someone you know are looking to access a medicine that is not yet approved where they live, we can support you. Contact us for more information.

References:

1. Cancer.org
2. Nhs.uk
3. IIs.org
4. Onureg (azacitidine) - Thesocialmedwork.com
5. Roche.com
6. Venclyxtob (vynclyxta/venetoclax) - Thesocialmedwork.com
7. Tibsovo (ivosidenib) - Thesocialmedwork.com

Disclaimer: This article is not meant to influence or impact the care provided by your treating physician. Please do not make changes to your treatment without first consulting your healthcare provider. This article is not intended to diagnose or treat illness or to influence treatment options. everyone.org is as diligent as possible in compiling and updating the information on this page. However, everyone.org does not guarantee the correctness and completeness of the information provided on this page.